China Approves Pirtobrutinib for Relapsed CLL/SLL After Positive BRUIN CLL-321 Results -

China Approves Pirtobrutinib for Relapsed CLL/SLL After Positive BRUIN CLL-321 Results

China’s National Medical Products Administration approved Pirtobrutinib (Jaypirca) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This decision follows its earlier approval by the U.S. FDA in December 2025 and offers a new option for patients whose disease progressed after prior covalent BTK inhibitors. The approval is based on results […]

China Approves Pirtobrutinib for Relapsed CLL/SLL After Positive BRUIN CLL-321 Results Read More »

FDA Grants Priority Review to Belzutifan Plus Pembrolizumab Based on LITESPARK-022 Results in High-Risk Kidney Cancer

Drug Approvals / li001

The FDA has granted Priority Review to new applications for belzutifan (Welireg) combined with Pembrolizumab (Keytruda). A decision is expected by June 19, 2026. The application is based on results from the Phase 3 LITESPARK-022 study. The trial included 1,841 patients with clear cell renal cell carcinoma (ccRCC) at high risk of recurrence after kidney surgery. Patients

FDA Grants Priority Review to Belzutifan Plus Pembrolizumab Based on LITESPARK-022 Results in High-Risk Kidney Cancer Read More »

KEYNOTE-B96 Sets New Standard as Pembrolizumab Improves Survival in Platinum-Resistant Ovarian Cancer

Clinical Trails / li001

The Phase 3 KEYNOTE-B96 study shows that adding Pembrolizumab (Keytruda) to weekly paclitaxel, with or without bevacizumab, helps patients with platinum-resistant ovarian cancer live longer. This is the first immune checkpoint inhibitor regimen to significantly improve overall survival in this setting. Patients who received the combination lived a median of 17.7 months compared with 14.0

KEYNOTE-B96 Sets New Standard as Pembrolizumab Improves Survival in Platinum-Resistant Ovarian Cancer Read More »

Study Identifies Key Tumor Cells Driving AITL, Revealing New Treatment Targets

Research Advances / li001

Researchers have identified a key driver of angioimmunoblastic T cell lymphoma (AITL), an aggressive type of T cell cancer. Using a mouse model, they discovered a unique subset of tumor cells called Double-Expressor (DE) Tfh cells. These cells grow rapidly, boost B cell expansion, and show inflammatory signaling, making them central to tumor progression. DE

Study Identifies Key Tumor Cells Driving AITL, Revealing New Treatment Targets Read More »

Adding MRI to Breast Screening Offers Limited Benefit for Most Women, Study Finds

Diagnostics / li001

A simulation study looked at whether adding MRI to standard digital breast tomosynthesis (DBT) improves breast cancer screening for women with dense breasts. The results show a trade-off: MRI can catch a few more cancers, but it also leads to many more false positives and unnecessary biopsies. For most average-risk women, adding MRI prevented only

Adding MRI to Breast Screening Offers Limited Benefit for Most Women, Study Finds Read More »

FDA Grants Priority Review to Rusfertide for Polycythemia Vera

Drug Approvals / li001

The U.S. Food and Drug Administration has granted Priority Review to the New Drug Application for rusfertide, a potential new treatment for adults with polycythemia vera (PV). A final approval decision is expected in the third quarter of 2026. PV causes the body to produce too many red blood cells, which thickens the blood and

FDA Grants Priority Review to Rusfertide for Polycythemia Vera Read More »

New Liver-Targeted Strategy Aims to Boost Immunotherapy in Advanced Melanoma

Clinical Trails / li001

Immunotherapy has greatly improved treatment for advanced melanoma, but liver metastases remain a major challenge. The liver can act as an “immune sink,” where special immune cells destroy the T cells that are supposed to fight cancer. This weakens the body’s overall immune response and makes liver tumors especially hard to treat. In the CHOPIN

New Liver-Targeted Strategy Aims to Boost Immunotherapy in Advanced Melanoma Read More »

New Strategy May Prevent Early PARP Inhibitor Resistance in Ovarian Cancer

Clinical Trails / li001

Researchers found that ovarian cancer cells quickly turn on a “pro-survival program” soon after treatment with PARP inhibitors begins. This fast response helps explain why these drugs can stop working, even if they seem effective at first. The team identified a protein called FRA1 as the key driver of this early resistance, allowing cancer cells

New Strategy May Prevent Early PARP Inhibitor Resistance in Ovarian Cancer Read More »

Polyamines Show Dual Role in Aging and Cancer Growth, Study Finds

Research Advances / li001

A study explains how polyamines, such as spermidine, can both support healthy aging and promote cancer growth. Their effect depends on which of two similar proteins they activate. In healthy cells, polyamines activate eIF5A1, which supports cellular cleanup (autophagy) and normal mitochondrial energy production, contributing to healthy aging. In cancer cells, polyamines activate a related

Polyamines Show Dual Role in Aging and Cancer Growth, Study Finds Read More »

Belzutifan Plus Keytruda Cuts Recurrence Risk in High-Risk Kidney Cancer, LITESPARK-022 Shows

Drug Approvals / li001

Results show that adding Welireg (belzutifan) to Keytruda after surgery significantly lowers the risk of cancer coming back in patients with clear cell renal cell carcinoma. The study found that the combination reduced the risk of recurrence or death by 28% compared with Keytruda alone. After 24 months, 81% of patients who received both drugs

Belzutifan Plus Keytruda Cuts Recurrence Risk in High-Risk Kidney Cancer, LITESPARK-022 Shows Read More »